Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Product-news    symbols : TAK    save search

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.84% H: 0.24% C: -0.14%

adzynma japan takeda approval injection
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.12% H: 0.0% C: -1.25%
NVS | $94.36 1.93% 0.0% 2.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.82% H: 0.28% C: -0.06%
XNCR | $18.385 -2.98% -3.07% 830K twitter stocktwits trandingview |
Health Technology
| | O: -0.96% H: 0.0% C: -5.61%
MOR | News | $17.96 -0.5% -0.5% 180K twitter stocktwits trandingview |
Health Technology
| | O: -4.71% H: 0.33% C: -2.65%
INCY | $52.3 -0.98% -0.99% 2.2M twitter stocktwits trandingview |
Health Technology
| | O: -2.37% H: 2.04% C: -2.95%

financial results results
Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®
Published: 2021-04-26 (Crawled : 12:15) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.23% H: 0.47% C: -0.53%
KPTI | $1.16 -9.38% -10.34% 1.4M twitter stocktwits trandingview |
Health Technology
| | O: -0.11% H: 5.12% C: 4.58%

europe authorized application
Global Roundup: Phico Therapeutics Wins CARB-X Funding for Bacteriophage Drug
Published: 2021-04-22 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.24% H: 0.0% C: -0.64%

funding drug
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Published: 2021-04-14 (Crawled : 00:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 1.09% C: 0.35%
BMY | $48.93 1.3% 0.0% 10M twitter stocktwits trandingview |
Health Technology
| | O: 0.27% H: 0.33% C: 0.09%
EXEL | $22.51 0.09% 0.09% 2.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.38% H: 4.2% C: 3.09%

treatment europe renal approval cell carcinoma nivolumab
Evotec and Takeda Enter Strategic RNA Targeting Drug Discovery and Development Alliance
Published: 2021-03-22 (Crawled : 11:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.56% H: 1.35% C: 1.02%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: -1.64% H: 1.2% C: 0.39%

drug discovery drug
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.36% H: 1.12% C: 0.96%
JNJ | News | $147.91 1.49% -0.03% 9.6M twitter stocktwits trandingview |
Health Technology
| | O: 0.09% H: 0.57% C: 0.42%

covid vaccine covid-19
Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema Attacks
Published: 2021-03-12 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: -1.13% H: 0.76% C: 0.66%

new drug treatment drug application hereditary angioedema
Takeda Completes Sale of TachoSil® to Corza Health
Published: 2021-02-01 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.13% H: 0.11% C: -0.45%

sales health
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]
Published: 2020-12-02 (Crawled : 15:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.45% H: 1.23% C: 0.55%


Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.